Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997966 | 0.95 | CNR2 (0.39) | TP53CNR1CNR2 | |
| SCHEMBL3006502 | 0.95 | KDM4E (0.38) | ENPP2 | |
| SCHEMBL2999297 | 0.94 | KMT2A (0.38) | KMT2AENPP2CNR1CNR2SMN1; SMN2 | |
| SCHEMBL13080275 | 0.93 | TP53 (0.36) | TP53 | |
| SCHEMBL13080272 | 0.93 | ENPP2 (0.39) | ENPP2CNR1CNR2 | |
| SCHEMBL13080276 | 0.92 | PDE4A (0.36) | TP53 | |
| SCHEMBL13080269 | 0.90 | ATM (0.38) | — | |
| SCHEMBL2990528 | 0.90 | ENPP2 (0.44) | ENPP2 | |
| SCHEMBL13080273 | 0.90 | TP53 (0.37) | TP53 | |
| SCHEMBL13080274 | 0.89 | PDE4A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283361-B2 | Heterocyclic urea derivatives and methods of use thereof | ASTRAZENECA AB (SE) | 2012-10-09 | — | — | US | disclosed |
| US-20100190745-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190745-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190745-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | UROD, UMPS, SLC14A1 | TP53 1641/4885KMT2A 3820/4885ENPP2 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.